Chemically-Modified Curcumin 2.24: A Novel Systemic Therapy for Natural Periodontitis in Dogs

References

• Suzuki N, Yoneda M, Hirofuji T. Mixed red-complex bacterial infection in periodontitis. Int J Dent. 2013;2013:587279. doi:10.1155/2013/587279
   PubMedGoogle Scholar
• Preshaw PM. Host response modulation in periodontics. Periodontol 2000. 2008;48:92–110. doi:10.1111/prd.2008.48.issue-1
   PubMed Web of Science ®Google Scholar
• Van Dyke TE. Commentary: periodontitis is characterized by an immuno-inflammatory host-mediated destruction of bone and connective tissues that support the teeth. J Periodontol. 2014;85(4):509–511. doi:10.1902/jop.2014.130701
   PubMed Web of Science ®Google Scholar
• Preshaw PM, Taylor JJ. How has research into cytokine interactions and their role in driving immune responses impacted our understanding of periodontitis? J Clin Periodontol. 2011;38(Suppl 11):60–84.
   Web of Science ®Google Scholar
• Ballini ACS, Farronato D, Cirulli N, et al. Periodontal disease and bone pathogenesis: the crosstalk between cytokines and porphyromonas gingivalis. J Biol Regul Homeost Agents. 2015;29(2):273–281.
   PubMed Web of Science ®Google Scholar
• Golub LM, Lee H-M. Periodontal therapeutics: current host-modulation agents and future directions. Periodontol 2000. 2020;82(1):186–204.
   Web of Science ®Google Scholar
• Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12(2):12–26. doi:10.1177/08959374980120010501
   PubMedGoogle Scholar
• Golub LM, Wolff M, Roberts S, Lee HM, Leung M, Payonk GS. Treating periodontal diseases by blocking tissue-destructive enzymes. J Am Dent Assoc. 1994;125(2):163–169; discussion 169–171. doi:10.14219/jada.archive.1994.0261
   Web of Science ®Google Scholar
• Golub LM, Elburki MS, Walker C, et al. Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases. Int Dent J. 2016;66(3):127–135. doi:10.1111/idj.2016.66.issue-3
   PubMed Web of Science ®Google Scholar
• Gu Y, Walker C, Ryan ME, Payne JB, Golub LM. Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine. J Oral Microbiol. 2012;4:19227.
   PubMedGoogle Scholar
• Sadowsky D, Nieman G, Barclay D, et al. Impact of chemically-modified tetracycline 3 on intertwined physiological, biochemical, and inflammatory networks in porcine sepsis/ARDS. Int J Burns Trauma. 2015;5(1):22–35.
   PubMed Web of Science ®Google Scholar
• Lee HM, Golub LM, Cao J, et al. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer. Curr Med Chem. 2001;8(3):257–260. doi:10.2174/0929867013373660
   PubMed Web of Science ®Google Scholar
• Roy SK, Kubiak BD, Albert SP, et al. Chemically modified tetracycline 3 prevents acute respiratory distress syndrome in a porcine model of sepsis + ischemia/reperfusion-induced lung injury. Shock. 2012;37(4):424–432. doi:10.1097/SHK.0b013e318245f2f9
   PubMed Web of Science ®Google Scholar
• Gu Y, Lee HM, Simon SR, Golub LM. Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase. Pharmacol Res. 2011;64(6):595–601. doi:10.1016/j.phrs.2011.05.011
   Web of Science ®Google Scholar
• Gu Y, Lee HM, Golub LM, Sorsa T, Konttinen YT, Simon SR. Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines. Ann Med. 2005;37(6):450–460. doi:10.1080/07853890500300386
   PubMed Web of Science ®Google Scholar
• Trachtman H, Futterweit S, Greenwald R, et al. Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells. Biochem Biophys Res Commun. 1996;229(1):243–248. doi:10.1006/bbrc.1996.1787
   Web of Science ®Google Scholar
• Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196(8):1025–1037. doi:10.1084/jem.20020760
   PubMed Web of Science ®Google Scholar
• Gyurko R, Van Dyke TE. The role of polyunsaturated omega-3 fatty acid eicosapentaenoic acid-derived resolvin E1 (RvE1) in bone preservation. Crit Rev Immunol. 2014;34(4):347–357. doi:10.1615/CritRevImmunol.2014009982
   Web of Science ®Google Scholar
• Serhan CN. Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. Prostaglandins Leukot Essent Fatty Acids. 2008;79(3–5):157–163. doi:10.1016/j.plefa.2008.09.012
   PubMed Web of Science ®Google Scholar
• Rey C, Nadjar A, Buaud B, et al. Resolvin D1 and E1 promote resolution of inflammation in microglial cells in vitro. Brain Behav Immun. 2016;55:249–259. doi:10.1016/j.bbi.2015.12.013
   PubMed Web of Science ®Google Scholar
• Kain V, Ingle KA, Colas RA, et al. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. J Mol Cell Cardiol. 2015;84:24–35. doi:10.1016/j.yjmcc.2015.04.003
   PubMed Web of Science ®Google Scholar
• Fredman G, Ozcan L, Spolitu S, et al. Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc Natl Acad Sci USA. 2014;111(40):14530–14535. doi:10.1073/pnas.1410851111
   PubMed Web of Science ®Google Scholar
• Liao Z, Dong J, Wu W, et al. Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARgamma/NF-kappaB pathway. Respir Res. 2012;13:110. doi:10.1186/1465-9921-13-110
   PubMed Web of Science ®Google Scholar
• Croasdell A, Sime PJ, Phipps RP. Resolvin D2 decreases TLR4 expression to mediate resolution in human monocytes. FASEB J. 2016;30(9):3181–3193. doi:10.1096/fj.201600375R
   Web of Science ®Google Scholar
• Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem. 2010;285(5):3451–3461. doi:10.1074/jbc.M109.044131
   PubMed Web of Science ®Google Scholar
• Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and chemR23 to regulate inflammation. J Immunol. 2007;178(6):3912–3917. doi:10.4049/jimmunol.178.6.3912
   PubMed Web of Science ®Google Scholar
• Ariel A, Serhan CN. Resolvins and protectins in the termination program of acute inflammation. Trends Immunol. 2007;28(4):176–183. doi:10.1016/j.it.2007.02.007
   Web of Science ®Google Scholar
• Golub LM, Ryan ME, Williams RC. Modulation of the host response in the treatment of periodontitis. Dent Today. 1998;17(10):102–106, 108–109.
   PubMedGoogle Scholar
• Lee HM, Ciancio SG, Tuter G, Ryan ME, Komaroff E, Golub LM. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J Periodontol. 2004;75(3):453–463. doi:10.1902/jop.2004.75.3.453
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gu Y, Lee HM, et al. Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. Curr Med Chem. 2012;19(25):4348–4358. doi:10.2174/092986712802884295
   PubMed Web of Science ®Google Scholar
• Zhang Y, Golub L M, Johnson F, Wishnia A. pKa, zinc- and serum albumin-binding of curcumin and two novel biologically- active chemically-modified curcumins. Curr Med Chem. 2012;19(25):4367–4375. doi:10.2174/092986712802884240
   Web of Science ®Google Scholar
• Elburki MS, Rossa C, Guimaraes MR, et al. A novel chemically modified curcumin reduces severity of experimental periodontal disease in rats: initial observations. Mediators Inflamm. 2014;2014:959471. doi:10.1155/2014/959471
   PubMed Web of Science ®Google Scholar
• Elburki MS, Moore DD, Terezakis NG, et al. A novel chemically modified curcumin reduces inflammation-mediated connective tissue breakdown in a rat model of diabetes: periodontal and systemic effects. J Periodontal Res. 2017;52(2):186–200. doi:10.1111/jre.2017.52.issue-2
   PubMed Web of Science ®Google Scholar
• Deng J, Gu Y, Lee HM, Raja V, Johnson F, Golub LM. Novel modified-curcumin: resolution of cytokines and MMPs in cell culture. J Dent Res. 2018;97(Special Issue A):0129.
   Google Scholar
• Gu Y, Deng J, Lee HM, et al. Chemically-modified-curcumin: resolvin activity in experimental diabetes. J Dent Res. 2017;96(Special Issue A):1173. doi:10.1177/0022034516680771
   Web of Science ®Google Scholar
• Elburki MS, Rossa C Jr., Guimaraes-Stabili MR, et al. A chemically modified curcumin (CMC 2.24) inhibits nuclear factor kappaB activation and inflammatory bone loss in murine models of LPS-induced experimental periodontitis and diabetes-associated natural periodontitis. Inflammation. 2017;40(4):1436–1449. doi:10.1007/s10753-017-0587-4
   PubMed Web of Science ®Google Scholar
• Elburki MS. A Novel Chemically Modified Curcumin as a Pleiotropic MMP-Inhibitor: Therapeutic Potential in Locally- and Systemically-Induced Periodontal (And Other) Connective Tissue Breakdown. University Libraries on behalf of The Graduate School at Stony Brook University: Oral Biology and Pathology, Stony Brook University; 2015.
   Google Scholar
• Zhang Y, McClain SA, Lee HM, et al. A novel chemically modified curcumin “normalizes” wound-healing in rats with experimentally induced type i diabetes: initial studies. J Diabetes Res. 2016;2016:5782904. doi:10.1155/2016/5782904
   PubMed Web of Science ®Google Scholar
• Xu L, Yu Z, Lee HM, et al. Characteristics of collagenase-2 from gingival crevicular fluid and peri-implant sulcular fluid in periodontitis and peri-implantitis patients: pilot study. Acta Odontol Scand. 2008;66(4):219–224. doi:10.1080/00016350802183393
   PubMed Web of Science ®Google Scholar
• Golub LM, Lee HM, Stoner JA, et al. Subantimicrobial-dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. J Periodontol. 2008;79(8):1409–1418. doi:10.1902/jop.2008.070623
   Web of Science ®Google Scholar
• White SCPM. Oral Radiology: Principles and Interpretation. Elsevier Health Sciences; 2014.
   Google Scholar
• Jeffcoat MK, Reddy MS. Advances in measurements of periodontal bone and attachment loss. Monogr Oral Sci. 2000;17:56–72.
   PubMedGoogle Scholar
• Zaki HA, Hoffmann KR, Hausmann E, Scannapieco FA. Is radiologic assessment of alveolar crest height useful to monitor periodontal disease activity? Dent Clin North Am. 2015;59(4):859–872. doi:10.1016/j.cden.2015.06.009
   Google Scholar
• Liao G, Simone J, Simon SR. Paracrine downregulation of Fc gamma RIII in human monocyte-derived macrophages induced by phagocytosis of nonopsonized particles. Blood. 1994;83(8):2294–2304. doi:10.1182/blood.V83.8.2294.2294
   PubMed Web of Science ®Google Scholar
• Golub LM, Ramamurthy NS, Llavaneras A, et al. A chemically modified nonantimicrobial tetracycline (CMT-8) inhibits gingival matrix metalloproteinases, periodontal breakdown, and extra-oral bone loss in ovariectomized rats. Ann NY Acad Sci. 1999;878:290–310. doi:10.1111/j.1749-6632.1999.tb07691.x
   Web of Science ®Google Scholar
• Albuquerque C, Morinha F, Requicha J, et al. Canine periodontitis: the dog as an important model for periodontal studies. Vet J. 2012;191(3):299–305. doi:10.1016/j.tvjl.2011.08.017
   PubMed Web of Science ®Google Scholar
• Nazir MA. Prevalence of periodontal disease, its association with systemic diseases and prevention. Int J Health Sci (Qassim). 2017;11(2):72–80.
   PubMedGoogle Scholar
• Yimam M, Brownell L, Do SG, et al. Protective Effect of UP446 on Ligature-Induced Periodontitis in Beagle Dogs. Dent J (Basel). 2019;7:2.
   Google Scholar
• Yoshioka H, Yoshimura A, Kaneko T, Golenbock DT, Hara Y. Analysis of the activity to induce toll-like receptor (TLR)2- and TLR4-mediated stimulation of supragingival plaque. J Periodontol. 2008;79(5):920–928. doi:10.1902/jop.2008.070516
   Web of Science ®Google Scholar
• Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22(2):240–273. doi:10.1128/CMR.00046-08
   PubMed Web of Science ®Google Scholar
• Matarese G, Curro M, Isola G, et al. Transglutaminase 2 up-regulation is associated with RANKL/OPG pathway in cultured HPDL cells and THP-1-differentiated macrophages. Amino Acids. 2015;47(11):2447–2455. doi:10.1007/s00726-015-2039-5
   Web of Science ®Google Scholar
• Nussbaum G, Shapira L. How has neutrophil research improved our understanding of periodontal pathogenesis? J Clin Periodontol. 2011;38(Suppl 11):49–59. doi:10.1111/jcpe.2011.38.issue-s11
   PubMed Web of Science ®Google Scholar
• Tornatore L, Thotakura AK, Bennett J, Moretti M, Franzoso G. The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends Cell Biol. 2012;22(11):557–566. doi:10.1016/j.tcb.2012.08.001
   PubMed Web of Science ®Google Scholar
• Li Q, Yu H, Zinna R, et al. Silencing mitogen-activated protein kinase-activated protein kinase-2 arrests inflammatory bone loss. J Pharmacol Exp Ther. 2011;336(3):633–642. doi:10.1124/jpet.110.172395
   PubMed Web of Science ®Google Scholar
• Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi’s sarcoma: an AIDS malignancy consortium study. J Clin Oncol. 2006;24(9):1389–1394. doi:10.1200/JCO.2005.04.2614
   PubMed Web of Science ®Google Scholar
• Ryan ME, Lee HM, Tenzler R, et al. Effects of short-term COL-3 on local biomarkers of periodontitis. J Dent Res. 2008;87(Special Issue 0040).
   Google Scholar
• Nyberg P, Moilanen M, Paju A, et al. MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells. J Dent Res. 2002;81(12):831–835. doi:10.1177/154405910208101207
   PubMed Web of Science ®Google Scholar
• Ramamurthy NS, Vernillo AT, Greenwald RA, et al. Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase. J Bone Miner Res. 1993;8(10):1247–1253. doi:10.1002/jbmr.5650081013
   PubMed Web of Science ®Google Scholar
• Hefti AF, Preshaw PM. Examiner alignment and assessment in clinical periodontal research. Periodontol 2000. 2012;59(1):41–60. doi:10.1111/prd.2012.59.issue-1
   Web of Science ®Google Scholar